Compare Lucid Group Inc (LCID) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Lucid Group Inc trades at $3.29 (market cap $1.32B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Lucid Group Inc is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lucid Group Inc for 45 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LCID | MRVI | |
|---|---|---|
Market Cap | $1.32B | $972.90M |
Volume | 8,737,624 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $21.67 | $9.00 |
52-Week Low | $3.29 | $2.83 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $4.22B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $3.36, down 2.33% amid ongoing operational challenges. The stock shows bearish technical signals with all moving averages indicating selling pressure, though oversold RSI levels suggest potential near-term bounce. Fundamentally, the company continues to burn cash with negative gross margins of -96.56% and widening losses, while recent news highlights delayed product launches and aggressive cost-cutting initiatives targeting $1.4 billion in savings.
LCID faces significant headwinds with persistent losses and cash burn threatening viability, though strategic partnerships and cost reduction efforts provide some optimism. The stock trades at deep discounts to sales and book value, but requires successful execution on new vehicle launches and substantial margin improvement to justify analyst consensus price target of $7.00, representing 109% upside from current levels.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
